AstraZeneca said it will invest $2 billion to expand its U.S. footprint in Maryland, onshoring parts of its rare-disease portfolio as part of a broader $50 billion pledge. The expansion is positioned as a strategic move to bolster domestic manufacturing capacity for complex biologics and rare-disease medicines. AstraZeneca’s plan underscores pharmaceutical firms’ growing interest in localized production for supply security.